NPC Archive Item: FDA safety warning for exenatide (Byetta▼)

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Reports from the USA of potentially fatal haemorrhagic or necrotising pancreatitis increase concerns over the safety of exenatide Action Healthcare professionals should be alert for signs or symptoms of […]

NPC Archive Item: Putting blood glucose control in type 2 diabetes into perspective

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Krumholz HM, Lee TH. Redefining quality – Implications of recent clinical trials. Perspective article. New Engl J Med 2008;28:2537–9 Intensive strategies to achieve tighter blood glucose control do not […]

NPC Archive Item: Updated guidance on management of type 2 diabetes from NICE

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 66: Type 2 diabetes: the management of type 2 diabetes (update) NICE has updated its guidance on the management of type 2 diabetes from 2002, incorporating […]

NPC Archive Item: NPC Podcast – 12th May 2008

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Self monitoring of blood glucose: less benefit than you might think [podcast]http://www.npc.nhs.uk/podcast/NPCiPodcast_12thMay08.mp3[/podcast] Subscribe to the NPC podcast via the iTunes store Subscribe to the NPC podcast via RSS feed

NPC Archive Item: Cases of lung cancer reported in clinical trials of inhaled insulin (Exubera®▼)

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. http://www.fda.gov/medwatch/safety/2008/safety08.htm#exubera The FDA in America has issued a Dear Healthcare Professional letter regarding cases of lung cancer in clinical trials and during post-marketing surveillance in patients treated with Pfizer’s […]